Clarke Low

Director, thoracic oncology @Intermountain. medical oncologist, interested in quality improvement, end-of-life care. tweets my own.

[Clarke Low @ClarkeLow]

Thanks @NarjustFlorezMD and @Florez_Lab for the beautiful pin to raise awareness of lung cancer, especially in women. #hearher #LCSM

[Clarke Low @ClarkeLow]

@PEHP2 please send DM so we can discuss a patient with Stage IV NSCLC needing to start chemoIO. PA submitted 1/6, being told no guarantee by 1/19. This is delaying care to patient's detriment. FDA-approved, NCCN-recommended treatment. 😠#FixPriorAuth #ASCOAdvocacy #LCSM

[Clarke Low @ClarkeLow]

CNS-only progression for patient on 1L entrectenib for ROS1 disease. Likely too many for gamma knife. What would you do? #LCSM

[Clarke Low @ClarkeLow]

@Dr_RShatsky Becky—I once had a 24 hour period where 4 of my patients died. It was sooo hard. I don’t think training prepares us for the loss that we all carry. I find comfort in my hope and belief that after this life I will see my patients again and give them a giant hug.

[Clarke Low @ClarkeLow]

Presentations by medical students/residents/fellows are the best. So exciting to have young colleagues share their perspective and enthusiasm. #ASCO2022

[Clarke Low @ClarkeLow]

@CharuAggarwalMD @ASCO @DrRiyazShah @DrJNaidoo @christine_lovly @LealTiciana @HwakeleeMD @LeciaSequist @JackWestMD @DrSteveMartin @ADesaiMD @esinghimd Unfortunate trial was terminated early as the difference was not statistically significant.
Also, Squam having higher MPR was not seen in CM816. Question of just not enough patients or difference in biology with different populations?

[Clarke Low @ClarkeLow]

Tempting to say receipt of adjuvant chemo for early stage NSCLC is a med onc quality metric, however, we must acknowledge some of this is not necessarily modifiable. A lot of patients aren't enthused by 5% OS benefit, for PD-L1 neg, EGFR neg pt's. #LCSM

[Clarke Low @ClarkeLow]

Congrats on great talk by @BrendanHeiden on developing operative quality score on early stage, N0, NSCLC. Might be most important talk I've heard so far, truly a #cancergroundshot #ASCO22 #LCSM. What would med onc and rad onc quality parameters look like...

[Clarke Low @ClarkeLow]

Good panel on treatment sequencing for NSCLC. First time I have ever heard treatment deescalation for lung cancer. I know we have had some progress, but deescalation seems a bit premature, no? #ASCO22 #LCSM

[Clarke Low @ClarkeLow]

@marklewismd @Shemari_12 Amen. I learn so much from my patients. And my colleagues cc: @marklewismd

[Clarke Low @ClarkeLow]

@ALKLungCancer Looking for a clinical trial for pt who progressed on alectinib, then lorlatinib. Lives in Western US. Any recommendations? #LCSM

[Clarke Low @ClarkeLow]

So proud to work with @MVanMeterMD at @intermtncancer Great summary at @SUMOncology #ASCO21 update meeting on lingering questions from OlympiA trial.

[Clarke Low @ClarkeLow]

Still waiting for @marklewismd to pull a Dwight Schrute at @SUMOncology

[Clarke Low @ClarkeLow]

“With virtual meetings we don’t return to the office because we never left the office.” @marklewismd speaks truth at a fantastic in-person meeting in Salt Lake by @SUMOncology. Great to be in-person.

[Clarke Low @ClarkeLow]

Grateful to be back at an in-person meeting and learning at the feet of my mentor ⁦@WAkerleyMD⁩ from ⁦@huntsmancancer⁩. Great update of progress in lung Ca. Thanks ⁦@SUMOncology⁩ for hosting this great event. #LCSM

[Clarke Low @ClarkeLow]

I miss in-person meeting, but I really like the question format with voting and moderators to select the questions. Far superior to random questions at the microphone. Please @ASCO find a way to keep this. #ASCO21

[Clarke Low @ClarkeLow]

@dean_fennell Congratulations on great presentation. Love changing "best supportive care" to "active symptom control" and including on both arms. #LCSM #ASCO21

[Clarke Low @ClarkeLow]

I don't tweet often, but I want to highlight practice changing stuff. Presser on IMpower010 (adj atezo, St II-IIIA NSCLC post chemo) is potentially that. HR 0.66 for recurrence/death in PD-L1 expressing NSCLC. Can't wait to see more data. Congrats @HwakeleeMD. #LCSM #ASCO21

[Clarke Low @ClarkeLow]

15min phone call w/ PBM for prior auth for selpercatinib that was denied. Questions are confusing to me, let alone my staff. Seems like they are designed to lead to denial. Love getting questions from "peer" who cannot pronounce hypocalcemia or hypomagnesemia. Sigh. #MedTwitter

[Clarke Low @ClarkeLow]

Really,really great @NEJM commentary: https://t.co/9g782M8K8d. What can I always offer my patients: "giving someone the space to be known". Simple, but profound. Thx @LisaRosenbaum17 for your beautiful writing.